<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842839</url>
  </required_header>
  <id_info>
    <org_study_id>ESCOPD-20181001</org_study_id>
    <nct_id>NCT03842839</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography for Assessment of the Treatment Effect of Tiotropium in Early Stage of COPD</brief_title>
  <official_title>Optical Coherence Tomography for Assessment of the Treatment Effect of Tiotropium in Early Stage of COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the reversibility of airway remodeling by Endobronchial Optical
      Coherence Tomography (EB-OCT). In this study, EB-OCT is used to assess the treatment effect
      of Tiotropium in early stage of COPD. Investigators recruit COPD patients in Grade A and
      Grade C according to GOLD 2019. Patients in Grade A will begin to use Tiotropium once daily,
      and EB-OCT, pulmonary function test and chest CT will be performed in baseline, 6 months, 1
      year and 2 year. Patients in Grade C will begin to use LABA+LAMA (including but not limited
      to Olodaterol / Tiotropium) or LAMA (Tiotropium) , same testing will be performed as patients
      in Grade A. Primary endpoint is airway parameters accessed by EB-OCT. And secondary end
      points are FEV1 and CT accessed pulmonary emphysema.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of inner airway area (Ai)</measure>
    <time_frame>Change of Ai from baseline at 2 years.</time_frame>
    <description>Change of Ai accessed by EB-OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of airway wall area (Aw)</measure>
    <time_frame>Change of Aw from baseline at 2 years.</time_frame>
    <description>Change of Aw accessed by EB-OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of airway wall area percentage (Aw%)</measure>
    <time_frame>Change of Aw% from baseline at 2 years.</time_frame>
    <description>Change of Aw% accessed by EB-OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Change of FEV1 from baseline at 2 years.</time_frame>
    <description>Change of FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of forced vital capacity (FVC)</measure>
    <time_frame>Change of FEV1 from baseline at 2 years.</time_frame>
    <description>Change of FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pulmonary emphysema index</measure>
    <time_frame>Change of emphysema index from baseline at 2 years.</time_frame>
    <description>Change of emphysema index accessed by computed tomography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Airway Remodeling</condition>
  <arm_group>
    <arm_group_label>COPD in Grade A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with Grade A COPD (according to GOLD 2019), will start to use Tiotropium once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD in Grade C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with Grade C COPD (according to GOLD 2019), will start to use Olodaterol + Tiotropium once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium will be used once daily for 2 years.</description>
    <arm_group_label>COPD in Grade A</arm_group_label>
    <arm_group_label>COPD in Grade C</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol / Tiotropium</intervention_name>
    <description>Tiotropium or dual bronchodilators will be used, (including but not limited to Olodaterol / Tiotropium) will be used once daily for 2 years.</description>
    <arm_group_label>COPD in Grade C</arm_group_label>
    <other_name>Spiolto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with COPD, and be labelled Grade A and C according to &quot;ABCD&quot;
             assessment tool of the 2019 GOLD.

        Exclusion Criteria:

          -  Patients with other lung diseases (such as bronchiectasis, pneumothorax, pleural
             effusion, airway deformation, lung surgery, etc.).

          -  Patients have poor compliance and are unwilling to receive medication regularly.

          -  Other complications of bronchoscopy or intolerance of bronchoscopy procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiyue Li, MD</last_name>
      <phone>8620-83062896</phone>
      <email>lishiyue@gzhmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shiyue Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>ShiYue Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Airway Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

